Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104630 · ClinicalTrials.gov registry record · Phase 2
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
A Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT07104630 is a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 85 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07104630, a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired. People may be eligible for this study if they have advanced stage NSCLC and feel short of breath some of the time. NSCLC survivors may also experience things like fatigue and a lower quality of life. Pulmonary rehabilitation is a type of supportive treatment that may improve these symptoms. This study has two parts. The first part is a randomized trial where half of the participants receive eight weeks of pulmonary rehabilitation. The other half of participants do not do pulmonary rehabilitation and instead receive the treatment that their doctors would normally recommend. The purpose of this part of the research study is to understand if pulmonary rehabilitation can help people with advanced stage NSCLC have better functioning and less shortness of breath. The other part of the research study is an interview study. The purpose of doing interviews is to understand any challenges or obstacles that people with advanced stage NSCLC may have regarding pulmonary rehabilitation, as well as oncology care providers have with their participants going to pulmonary rehabilitation.
Conditions Studied
Interventions
- BEHAVIORAL Pulmonary Rehabilitation (PR)
- OTHER No intervention: Usual care
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07104630
The ClinicalTrials.gov registry entry for NCT07104630 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pulmonary Rehabilitation (PR) is the first listed.
NCT07104630 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07104630 about?
NCT07104630 is a clinical study titled "Pulmonary Rehabilitation in Advanced Lung Cancer Survivors". This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired. People may be eligible for this study if they have advanced stage NSCLC and feel short of breath some of th...
What is the current status of trial NCT07104630?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2026-03. Estimated completion is 2028-12.
What conditions does trial NCT07104630 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (Stage III), Non-small Cell Lung Cancer Stage IV.
What interventions are being tested in trial NCT07104630?
The interventions under investigation include: Pulmonary Rehabilitation (PR) (BEHAVIORAL), No intervention: Usual care (OTHER).
Who is sponsoring clinical trial NCT07104630?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104630 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.